Ubs Group Ag Maxcyte, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Maxcyte, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 68,051 shares of MXCT stock, worth $292,619. This represents 0.0% of its overall portfolio holdings.

Number of Shares

68,051

Previous 49,602 37.19%

Holding current value

$292,619

Previous $194,000 36.08%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.68 - $5.06 $67,892 - $93,351	18,449 Added 37.19%	68,051 $264,000
Q2 2024 Aug 13, 2024	SELL	$3.63 - $5.0 $169,992 - $234,150	-46,830 Reduced 48.56%	49,602 $194,000
Q1 2024 May 13, 2024	BUY	$3.94 - $5.38 $3,380 - $4,616	858 Added 0.9%	96,432 $404,000
Q4 2023 Feb 09, 2024	BUY	$2.6 - $5.24 $79,671 - $160,569	30,643 Added 47.19%	95,574 $449,000
Q3 2023 Nov 09, 2023	SELL	$3.02 - $5.1 $18,077 - $30,528	-5,986 Reduced 8.44%	64,931 $202,000
Q2 2023 Aug 11, 2023	BUY	$3.69 - $5.35 $69,600 - $100,911	18,862 Added 36.23%	70,917 $325,000
Q1 2023 May 12, 2023	BUY	$4.03 - $5.89 $33,634 - $49,157	8,346 Added 19.09%	52,055 $257,000
Q4 2022 Feb 08, 2023	BUY	$4.92 - $7.4 $161,228 - $242,498	32,770 Added 299.57%	43,709 $238,000
Q3 2022 Nov 10, 2022	SELL	$4.52 - $6.51 $37,805 - $54,449	-8,364 Reduced 43.33%	10,939 $71,000
Q2 2022 Aug 10, 2022	BUY	$3.59 - $6.81 $59,163 - $112,228	16,480 Added 583.78%	19,303 $91,000
Q1 2022 May 16, 2022	SELL	$5.26 - $10.84 $215,091 - $443,269	-40,892 Reduced 93.54%	2,823 $20,000
Q4 2021 Feb 14, 2022	BUY	$8.87 - $12.94 $305,846 - $446,184	34,481 Added 373.41%	43,715 $445,000
Q3 2021 Nov 15, 2021	BUY	$12.21 - $17.2 $112,747 - $158,824	9,234 New	9,234 $113,000

Others Institutions Holding MXCT

# of Institutions

124

Shares Held

65.6M

Call Options Held

Put Options Held

View Full List

About MAXCYTE, INC.

Ticker MXCT
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 101,724,000
Market Cap $437M
Description
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...

More about MXCT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account